Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Biol Blood Marrow Transplant ; 23(11): 1989-1997, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-28712934

RESUMEN

Mixed chimerism (MC), a persistent or increasing number of host cells after allogeneic hematopoietic stem cell transplantation (HSCT), is a predictor of disease relapse. Donor lymphocyte infusions (DLI) have the potential to enhance the graft-versus-malignancy (GVM) effect, reducing the risk of relapse in patients with MC. Hence, in addition to utilizing DLI in the relapsed setting, there is a motivation to pursue pre-emptive DLI for patients in complete remissions after HSCT. To assess the safety and efficacy of DLI, records of 86 patients who received DLI between 2003 and 2015 at a single institution were studied retrospectively. Patients who received DLI included 50 patients with relapsed/residual (RR) disease, 29 patients with emerging MC without detectable disease, and 7 patients in an "other" cohort who had neither RR disease nor emerging MC after HSCT. DLI were administered using a dose-escalation protocol. After DLI, 93% of MC patients converted to full donor chimerism (FDC). Nonrelapsed patients (MC and other) reported high overall survival (OS) at 1 and 5 years (83% at 1 year, 70% at 5 years for MC; 86% at 1 year, 69% at 5 years for other) and was statistically superior to 5-year OS for RR patients (nonrelapsed 69% versus RR 28%; P = .00032). Improved survival correlated with successful conversion to FDC after DLI for RR and MC cohorts: 71% 2-year OS for patients converted to FDC versus 13% for patients who failed to achieve FDC (P < .0001). DLI for nonrelapsed patients was associated with a superior 5-year progression-free survival (PFS) of 71% compared with 18% 5-year PFS in the RR group (P < .0001). Relapse/progressive disease was the most frequent cause of death (41%). Seven MC (24%), 2 other (29%), and 39 RR patients (78%) relapsed or did not respond after DLI. Overall, 6 patients (7%) died of graft-versus-host disease after DLI. Our results demonstrate a successful dose-escalation approach for nonrelapsed patients that correlated with high survival and a high rate of achieving FDC in MC and RR populations. DLI remain a viable option to boost the GVM effect in the relapsed setting and may pre-emptively protect against relapse in MC populations after HSCT.


Asunto(s)
Neoplasias Hematológicas/terapia , Trasplante Homólogo/métodos , Adolescente , Adulto , Anciano , Quimerismo , Supervivencia sin Enfermedad , Femenino , Neoplasias Hematológicas/mortalidad , Neoplasias Hematológicas/patología , Humanos , Transfusión de Linfocitos/métodos , Masculino , Persona de Mediana Edad , Recurrencia , Análisis de Supervivencia , Factores de Tiempo , Donantes de Tejidos , Quimera por Trasplante , Adulto Joven
2.
Blood ; 118(23): e180-3, 2011 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-22001389

RESUMEN

Histocompatibility testing for stem cell and solid organ transplantation has become increasingly complex as newly discovered HLA alleles are described. HLA typing assignments reported by laboratories are used by physicians and donor registries for matching donors and recipients. To communicate effectively, a common language for histocompatibility terms should be established. In early 2010, representatives from Clinical, Registry, and Histocompatibility organizations joined together as the Harmonization of Histocompatibility Typing Terms Working Group to define a consensual language for laboratories, physicians, and registries to communicate histocompatibility typing information. The Working Group defined terms for HLA typing resolution, HLA matching, and a format for reporting HLA assignments. In addition, definitions of verification typing and extended typing were addressed. The original draft of the Definitions of Histocompatibility Typing Terms was disseminated to colleagues from each organization to gain feedback and create a collaborative document. Commentary gathered during this 90-day review period were discussed and implemented for preparation of this report. Histocompatibility testing continues to evolve; thus, the definitions agreed on today probably will require refinement and perhaps additional terminology in the future.


Asunto(s)
Alergia e Inmunología/normas , Guías como Asunto , Histocompatibilidad/inmunología , Terminología como Asunto , Inmunología del Trasplante , Humanos
3.
Front Oral Health ; 2: 764784, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-35048065

RESUMEN

Streptococcus mutans serotype k strains comprise <3% of oral isolates of S. mutans but are prominent in diseased cardiovascular (CV) tissue. Collagen binding protein (CBP) genes, cbm and cnm, are prevalent in serotype k strains and are associated with endothelial cell invasion. Nicotine increases biofilm formation by serotype c strains of S. mutans, but its effects on serotype k strains and strains with CBP are unknown. Saliva contains arginine which alters certain properties of the extracellular polysaccharides (EPS) in S. mutans biofilm. We examined whether nicotine and arginine affect sucrose-induced biofilm of S. mutans serotypes k (n = 23) and c (n = 10) strains with and without CBP genes. Biofilm mass, metabolism, bacterial proliferation, and EPS production were assessed. Nicotine increased biomass and metabolic activity (p < 0.0001); arginine alone had no effect. The presence of a CBP gene (either cbm or cnm) had a significant effect on biofilm production, but serotype did not. Nicotine increased bacterial proliferation and the effect was greater in CBP + strains compared to strains lacking CBP genes. Addition of arginine with nicotine decreased both bacterial mass and EPS compared to biofilm grown in nicotine alone. EPS production was greater in cnm + than cbm + strains (p < 0.0001). Given the findings of S. mutans in diseased CV tissue, a nicotine induced increase in biofilm production by CBP + strains may be a key link between tobacco use and CV diseases.

4.
Pediatr Neurol ; 39(4): 293-4, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18805373

RESUMEN

A 12-year-old African American boy with mental retardation and Asperger's disorder presented with acute psychosis. Antiphospholipid antibody testing with enzyme-linked immunosorbent assay showed increased levels of immunoglobulin G anticardiolipin antibodies in the cerebrospinal fluid, but not in the serum. Although antiphospholipid antibodies have been reported in the serum of patients with thrombotic and neurologic disorders, there are only a few reports of these antibodies in cerebrospinal fluid. This finding is consistent with a recent report of antiphospholipid antibodies found in the cerebrospinal fluid of adults with acute psychosis.


Asunto(s)
Anticuerpos Antifosfolípidos/líquido cefalorraquídeo , Inmunoglobulina G/líquido cefalorraquídeo , Trastornos Psicóticos/líquido cefalorraquídeo , Anticuerpos Antifosfolípidos/inmunología , Síndrome de Asperger/líquido cefalorraquídeo , Síndrome de Asperger/inmunología , Niño , Ensayo de Inmunoadsorción Enzimática , Humanos , Inmunoglobulina G/inmunología , Discapacidad Intelectual/líquido cefalorraquídeo , Discapacidad Intelectual/inmunología , Masculino , Trastornos Psicóticos/inmunología
5.
J Neuroimmunol ; 190(1-2): 151-6, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17868908

RESUMEN

Antiphospholipid antibodies (aPL) have been reported in the cerebrospinal fluids (CSF) of neurology patients but no CSF studies with psychiatric patients exist. We tested serum from 100 hospitalized psychotic patients having hallucinations and/or delusions for aPL. Patients with positive serum aPL findings were asked to submit CSF for aPL testing. Five CSF samples had aPL specificities not found in the patient's serum suggesting the possibility of intrathecal synthesis. Specificity and isotype discordance between CSF and blood aPL in these psychiatric patients implicates a central nervous system independent autoimmune process that may have an underlying association with the pathophysiology of their diseases.


Asunto(s)
Autoanticuerpos/inmunología , Química Encefálica/inmunología , Encéfalo/inmunología , Fosfolípidos/inmunología , Trastornos Psicóticos/inmunología , Adolescente , Adulto , Anciano , Autoanticuerpos/sangre , Autoanticuerpos/líquido cefalorraquídeo , Enfermedades Autoinmunes del Sistema Nervioso/sangre , Enfermedades Autoinmunes del Sistema Nervioso/líquido cefalorraquídeo , Enfermedades Autoinmunes del Sistema Nervioso/inmunología , Trastorno Bipolar/sangre , Trastorno Bipolar/líquido cefalorraquídeo , Trastorno Bipolar/inmunología , Encéfalo/metabolismo , Encéfalo/fisiopatología , Femenino , Alucinaciones/sangre , Alucinaciones/líquido cefalorraquídeo , Alucinaciones/inmunología , Humanos , Metabolismo de los Lípidos/inmunología , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Trastornos Psicóticos/sangre , Trastornos Psicóticos/líquido cefalorraquídeo , Esquizofrenia/sangre , Esquizofrenia/líquido cefalorraquídeo , Esquizofrenia Paranoide/sangre , Esquizofrenia Paranoide/líquido cefalorraquídeo , Esquizofrenia Paranoide/inmunología , Sensibilidad y Especificidad
6.
Autoimmun Rev ; 5(1): 76-83, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16338215

RESUMEN

We recently described a hitherto unrecognized family of autoantibodies that become unmasked (detectable) subsequent to oxidation-reduction (redox) reactions. These masked redox-reactive autoantibodies are not detectable by using conventional immunoassays. Additional experimentation has demonstrated that autoantibodies in the blood of patients with autoimmune diseases can be masked (become undetectable) by exposure to oxidizing agents. Simultaneous masking and unmasking of different autoantibodies in a given patient's serum or plasma is evidence that immune complexes are not the source of redox-reactive autoantibodies. We propose that a mechanism responsible for unmasking-masking antibody specificities requires nitrosylation of tyrosine residues in the hypervariable or complementarity determining regions of the antibodies' antigen-binding sites. Other laboratories, selected by us for their respective expertise, have studied our redox-reacted and control serum and/or antibody preparations and have found an expanding array of autoantibody specificities. The gathering data suggest that certain autoimmune diseases may involve redox disorders rather than a failure to deplete, suppress, tolerate or divert self-directed B cell activity. The persistence and fluctuation of redox-reactive autoantibodies suggest that they are manifestations of an as yet undefined natural selective pressure on the evolution of the immunological system. We propose that they are the "contrivances" suggested by Paul Ehrlich more than a hundred years ago, and that these antibodies perform important physiological and pathophysiological functions.


Asunto(s)
Especificidad de Anticuerpos/inmunología , Autoanticuerpos/sangre , Enfermedades Autoinmunes/sangre , Autoinmunidad/inmunología , Linfocitos B/inmunología , Animales , Autoanticuerpos/inmunología , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/patología , Linfocitos B/patología , Humanos , Inmunoensayo/métodos , Oxidación-Reducción
7.
Prog Lipid Res ; 42(3): 176-237, 2003 May.
Artículo en Inglés | MEDLINE | ID: mdl-12689618

RESUMEN

Antiphospholipid antibodies (aPL) are immunoglobulins of IgG, IgM and IgA isotypes that target phospholipid (PL) and/or PL-binding plasma proteins. Detection of aPL in the laboratory is done currently by both immunoassays and functional coagulation tests. Convention defines aPL specificity in immunoassays according to the particular PL substrate present, for example aPS represents antiphosphatidylserine antibodies. This may be technically incorrect inasmuch as a particular PL may be responsible for binding and highly concentrating a specific plasma protein, the latter then becomes the target for the aPL. The binding of beta(2)GP-I (apolipoprotein H) to the negatively charged PL, cardiolipin (CL) provides a good example of this circumstance. In contrast, aPL which specifically prolong coagulation times in in vitro are called lupus anticoagulants (LA). The precise PL target(s) of the aPL responsible for LA activities are unknown and often debated. The persistent finding of aPL in patients in association with abnormal blood clotting and a myriad of neurological, obstetrical and rheumatic disorders often compounded by autoimmune diseases has led to an established clinical diagnosis termed antiphospholipid syndrome (APS). The common denominator for these APS patients is the presence of circulating aPL on two or more occasions and the observation of events attributable to abnormal or accelerated blood clotting somewhere in vivo. The purpose of this review is to collect, collate, and consolidate information concerning aPL.


Asunto(s)
Anticuerpos Antifosfolípidos/sangre , Síndrome Antifosfolípido/diagnóstico , Anticuerpos Anticardiolipina/sangre , Autoanticuerpos/sangre , Rechazo de Injerto/inmunología , Humanos , Inmunoensayo/métodos , Trasplante de Órganos , Fosfatidilcolinas/inmunología , Fosfatidilserinas/inmunología
8.
Comp Med ; 56(5): 426-34, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17069028

RESUMEN

Surgical implantation of devices into the abdomen of PL/J mice was associated with fatal hemorrhage at 9 to 11 d after surgery. Coagulation profiles were evaluated to determine the underlying cause of this effect. The mean activated partial thromboplastin time (aPTT) of untreated PL/J mice was significantly higher than that of BALB/cByJ and C57BL/6J strains. The addition of human plasmas deficient in factors VIII, XI, or XII, prekallikrein, or high molecular-weight kininogen corrected the elevated aPTT of PL/J mice, but correction did not occur when factor IX-deficient human plasma was added. When compared to an assigned factor IX activity of 100% for pooled plasma from BALB/cByJ mice, C57BL/6J and PL/J mice revealed percent activities of 67% and 16%, respectively. PL/J mice could represent a new model for the study of pathogenesis and therapy of mild factor IX deficiency that is expressed and becomes clinically apparent secondary to major surgery.


Asunto(s)
Modelos Animales de Enfermedad , Hemofilia B/complicaciones , Trastornos Hemorrágicos/etiología , Ratones Endogámicos , Animales , Conducta Animal , Coagulación Sanguínea , Susceptibilidad a Enfermedades , Factor IX/genética , Hemofilia B/sangre , Trastornos Hemorrágicos/sangre , Isotipos de Inmunoglobulinas/sangre , Implantes Experimentales/efectos adversos , Ratones , Complicaciones Posoperatorias
9.
Autoimmunity ; 48(5): 344-51, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25672931

RESUMEN

A robust blood biomarker is urgently needed to facilitate early prognosis for those at risk for Alzheimer's disease (AD). Redox reactive autoantibodies (R-RAAs) represent a novel family of antibodies detectable only after exposure of cerebrospinal fluid (CSF), serum, plasma or immunoglobulin fractions to oxidizing agents. We have previously reported that R-RAA antiphospholipid antibodies (aPLs) are significantly decreased in the CSF and serum of AD patients compared to healthy controls (HCs). These studies were extended to measure R-RAA aPL in serum samples obtained from Alzheimer's Disease Neuroimaging Initiative (ADNI). Serum samples from the ADNI-1 diagnostic groups from participants with mild cognitive impairment (MCI), AD and HCs were blinded for diagnosis and analyzed for R-RAA aPL by ELISA. Demographics, cognitive data at baseline and yearly follow-up were subsequently provided by ADNI after posting assay data. As observed in CSF, R-RAA aPL in sera from the AD diagnostic group were significantly reduced compared to HC. However, the sera from the MCI population contained significantly elevated R-RAA aPL activity relative to AD patient and/or HC sera. The data presented in this study indicate that R-RAA aPL show promise as a blood biomarker for detection of early AD, and warrant replication in a larger sample. Longitudinal testing of an individual for increases in R-RAA aPL over a previously established baseline may serve as a useful early sero-epidemiologic blood biomarker for individuals at risk for developing dementia of the Alzheimer's type.


Asunto(s)
Enfermedad de Alzheimer/sangre , Enfermedad de Alzheimer/diagnóstico , Anticuerpos Antifosfolípidos/sangre , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/inmunología , Anticuerpos Antifosfolípidos/inmunología , Biomarcadores , Ensayo de Inmunoadsorción Enzimática , Femenino , Estudios de Seguimiento , Humanos , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Masculino , Proyectos Piloto , Pronóstico , Reproducibilidad de los Resultados
11.
Hum Immunol ; 72(12): 1214-6, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21723898

RESUMEN

Histocompatibility testing for stem cell and solid organ transplantation has become increasingly complex as newly discovered human leukocyte antigen (HLA) alleles are described. HLA typing assignments reported by laboratories are used by physicians and donor registries for matching donors and recipients. To communicate effectively, a common language for histocompatibility terms should be established. In early 2010, representatives from clinical, registry, and histocompatibility organizations joined together as the Harmonization of Histocompatibility Typing Terms Working Group to define a consensual language for laboratories, physicians and registries to communicate histocompatibility typing information. The Working Group defined terms for HLA typing resolution, HLA matching and a format for reporting HLA assignments. In addition, definitions of verification typing and extended typing were addressed. The original draft of the Definitions of Histocompatibility Typing Terms was disseminated to colleagues from each organization to gain feedback and create a collaborative document. Commentary gathered during this 90-day review period were discussed and implemented for preparation of this report. Histocompatibility testing continues to evolve thus, the definitions agreed upon today, likely will require refinement and perhaps additional terminology in the future.


Asunto(s)
Antígenos HLA/inmunología , Trasplante de Células Madre Hematopoyéticas , Células Madre Hematopoyéticas/inmunología , Prueba de Histocompatibilidad/normas , Histocompatibilidad/inmunología , Consenso , Antígenos HLA/clasificación , Prueba de Histocompatibilidad/métodos , Humanos , Sistema de Registros/normas , Trasplante Homólogo
12.
Autoimmunity ; 42(8): 646-52, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19886736

RESUMEN

There is no universally acceptable inclusive laboratory biomarker for the diagnosis and staging of neurodegenerative diseases, for example, Alzheimer's. There is an abnormal increase of oxidative stress in the central nervous system (CNS) of Alzheimer's patients that causes oxidation of proteins, lipids and DNA. We have published that the antiphospholipid (aPL) autoantibodies that are members of the redox-reactive autoantibody (R-RAA) family, are significantly decreased or absent in the cerebrospinal fluids of autopsy-confirmed Alzheimer's disease (AD) patients. Because of the known elevation of oxidation-induced damage in the CNS and the abnormal enrichment of redox reactive metals in postmortem AD brains, we questioned if the R-RAA in the blood of AD patients might also show a departure from the normal aPL levels. We compared 16 AD serum samples to 17 serum samples, from age-matched volunteer blood donors. Each serum was tested before and after oxidation for four aPL specificities by using an in-house ELISA. Comparisons between the AD and normal populations revealed highly significant differences. In-sample Fisher's linear discriminate analysis found a sensitivity of 88% and a specificity of 94%. In-sample Classification and Regression Tree analysis (CART) found a sensitivity of 84% and a specificity of 100%. This study is the first to indicate that blood tests for R-RAA may be used as a laboratory criterion for an Alzheimer's diagnosis.


Asunto(s)
Enfermedad de Alzheimer/sangre , Enfermedad de Alzheimer/inmunología , Anticuerpos Antifosfolípidos/sangre , Anticuerpos Antifosfolípidos/inmunología , Suero/inmunología , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/diagnóstico , Anticuerpos Antifosfolípidos/metabolismo , Estudios de Casos y Controles , Ensayo de Inmunoadsorción Enzimática , Femenino , Hemina/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Oxidación-Reducción , Fosfolípidos/inmunología , Sensibilidad y Especificidad
13.
J Autoimmun ; 24(4): 311-7, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15927793

RESUMEN

Blood from healthy donors was found to contain a variety of autoantibodies after being cultured overnight in commercial blood culture bottles. Paradoxically some autoantibodies in the blood of patients with autoimmune diseases were no longer detectable when similarly cultured. By a process of elimination it was revealed that hemin was responsible for the conversion of antibody-negative blood to antibody-positive blood, as well as for the conversion of antibody-positive blood to antibody-negative blood. By using a purified component system of hemin and immunoglobulin, and an iron-free congener of hemin, we have shown that the appearance and/or disappearance of antibodies occur uniquely in the presence of coordinated iron and in the absence of antioxidants such as vitamin C. The oxidation-reduction (redox) reactions used to demonstrate the appearance and disappearance of autoantibodies have been performed in vitro. Whether the reactions we have observed have a parallel in vivo remains to be determined. It is clear from our findings that normal individuals have immunoglobulin molecules which can exhibit autoantibody binding capacity, and that at least some autoantibodies in autoimmune individuals can have their binding capacity masked by exercise of a natural redox system. These preliminary findings need further investigation but they already hint that some of our apparently well based views on autoimmunity might be expanded to include a role for masked and unmasked autoantibodies.


Asunto(s)
Autoanticuerpos/análisis , Sangre Fetal/química , Hemina/química , Inmunoglobulina G/análisis , Hierro/química , Autoanticuerpos/química , Enfermedades Autoinmunes/sangre , Conservación de la Sangre , Hemina/análisis , Humanos , Inmunoglobulina G/química , Hierro/análisis , Oxidación-Reducción
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA